Tipranavir

• Description :

  Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-protease inhibitor (PI) -resistant HIV-1 isolates with IC50s of 66-410 nM[1][2]. Tipranavir inhibits SARS-CoV-2 3CLpro activity[3].

• Product Name Alternative :

  PNU-140690

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319, H320

• Target :

  HIV; HIV Protease; SARS-CoV

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; Metabolic Enzyme/Protease

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/Tipranavir.html

• Purity :

  98.0

• Solubility :

  DMSO : 200 mg/mL (ultrasonic) |Ethanol : ≥ 50 mg/mL

• Smiles :

  O=C1C([C@H](CC)C2=CC=CC(NS(C3=CC=C(C(F)(F)F)C=N3)(=O)=O)=C2)=C(O)C[C@](CCC4=CC=CC=C4)(CCC)O1

• Molecular Formula :

  C31H33F3N2O5S

• Molecular Weight :

  602.66

• Precautions :

  H315, H319, H320

• References & Citations :

  [1]Aoki M, et al. Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1. J Virol. 2012 Dec;86 (24) :13384-96.|[2]Li F, et al. Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice. Drug Metab Dispos. 2010 May;38 (5) :871-8.|[3]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  HIV-1

• CAS Number :

  [174484-41-4]